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The utilization of next-generation sequencing technology to interrogate multiple genes
simultaneously is being utilized more frequently in hereditary cancer testing. While
this has benefits of reducing cost and allowing clinicians to cast a wide net in the
elucidation of their patient’s cancer, panel testing has the potential to reveal unexpected
information. We report on a proband with pathogenic variants resulting in two different
hereditary colon cancer syndromes. A 39-year-old male with a history of colon cancer,
more than 20 colon polyps and a family history of colon cancer presented for genetic
counseling. Testing with a 7-gene high-risk hereditary colon cancer panel identified a
homozygous pathogenic variant, c.1187G>A (p.Gly396Asp) in MUTYH, and a likely
pathogenic duplication of exon 7 in MSH2. Since this test result, the proband’s mother
was diagnosed with colon cancer; subsequent genetic testing confirmed she also
carries the likely pathogenic duplication in the MSH2 gene. Although the cancer risk in
individuals who carry multiple pathogenic variants has not been established for combined
biallelic MUTYH-associated polyposis and Lynch syndrome, the identification of multiple
pathogenic variants does allow for screening for cancers associatedwith both syndromes
and has implications for cancer risk for family members. In particular, this has significant
impact on those who test negative for a known familial pathogenic variant, yet could be
still be at risk for cancer due to a second pathogenic variant in a family. More information
is needed on the frequency of occurrence of multiple pathogenic variants, as well as the
phenotypic spectrum when multiple pathogenic variants are present.
Keywords: next-generation sequencing, hereditary cancer, genetic counseling, MUTYH-associated polyposis,
Lynch syndrome, case report
INTRODUCTION
A 39-year-old male who works as a general manager presented to the Cancer Genetics Risk
Assessment program for genetic counseling due to a personal history of rectal cancer at the age
of 38. In addition to the rectal cancer, more than 20 adenomatous polyps were found in his
colon. He underwent a laparoscopic total proctocolectomy with ileoanal J-pouch anastomosis
and diverting loop ileostomy. The tumor was a superficially invasive, moderately differentiated
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adenocarcinoma, arising within a background of adenoma and
multifocal high-grade dysplasia. Immunohistochemistry staining
as part of the hospital’s universal screening program for
Lynch syndrome displayed intact MLH1, MSH2, MSH6, and
PMS2 proteins; microsatellite instability (MSI) testing was not
performed. The proband’s father had a history of basal cell
carcinoma at the age of 58 and five colon polyps at the age of 61.
Colon cancer was reported in the proband’s paternal uncle at the
age of 70 and a paternal great-grandmother in her 50s. Finally, the
proband reported that his mother had a hysterectomy at a young
age due to an unspecified gynecologic cancer.
The proband underwent genetic testing with a 7-gene high-
risk hereditary colon cancer panel which screened for variants
in the APC, EPCAM, MLH1, MSH2, MSH6, MUTYH, and
PMS2 genes. The proband was found to carry a homozygous
pathogenic variant, c.1187G>A (p.Gly396Asp) in MUTYH, and
a likely pathogenic duplication of exon 7 in MSH2 (Figure 1).
The c.1187G>A (p.Gly396Asp) variant is a common cause
of MUTYH-associated polyposis in individuals of Northern
European ancestry and experimental studies have shown that
this missense variant disrupts MUTYH protein function (Aretz
et al., 2006; Ali et al., 2008). While the exact position of the
exon 7 duplication inMSH2was not conclusively determined, the
most likely explanation is that it occurs in tandem, which would
likely result in a frameshift leading to a premature translational
stop signal and an absent or disrupted MSH2 protein. A similar
duplication of exon 7 in the MSH2 gene has been reported
previously in a patient affected with colorectal cancer (Casey
et al., 2005). Both MUTYH and MSH2 variants were confirmed
by using an appropriate orthogonal method.
The proband’s parents subsequently underwent genetic
counseling. The proband’s mother clarified that she had a
diagnosis of vulvar cancer at the age of 34 and five colon polyps
at the age of 50. She reported a family history of colorectal cancer
in her maternal grandmother at an unknown age, her maternal
aunt at the age of 50 and a maternal first cousin at the age of
53; all of this was unknown at the time of the proband’s initial
genetic counseling appointment (Figure 2). While the proband’s
mother was waiting for her genetic test results, she was diagnosed
with an invasive, well-differentiated mucinous adenocarcinoma
of the cecum at the age of 63. TheMSH2 andMSH6 proteins were
absent by immunohistochemistry staining on the tumor, while
MLH1 and PMS2 were preserved; MSI was not performed.
Genetic testing confirmed that each parent was heterozygous
for the pathogenic variant c.1187G>A (p.Gly396Asp) in the
MUTYH gene. The proband’s mother was also found to carry the
likely pathogenic duplication in theMSH2 gene.
BACKGROUND
Lynch syndrome is an autosomal dominant condition caused by a
pathogenic variant in one of four mismatch repair (MMR) genes
or in EPCAM, a gene involved in epithelial cell adhesion. Lynch
syndrome is characterized by an increased risk for colorectal
cancer, as well as cancers of the endometrium, ovary, stomach,
small intestine, hepatobiliary tract, urinary tract, and brain
(Kohlmann and Gruber, 2004/2014; Cohen and Leininger, 2014).
The lifetime risk for cancer among individuals with Lynch
syndrome ranges widely, depending on the specific mismatch
repair gene that is involved. The lifetime risk for colorectal cancer
associated with a pathogenic variant in MSH2 approaches 60%,
and females with a pathogenic variant inMSH2 have up to a 40%
lifetime risk for endometrial cancer.
MUTYH-associated polyposis (MAP), an autosomal recessive
condition caused by biallelic pathogenic variants in MUTYH,
is characterized by multiple colorectal adenomas arising in
adulthood and increased colorectal cancer risk. Lifetime risk
for colorectal cancer among patients with biallelic pathogenic
variants in MUTYH is estimated to be at least 43 to almost
100% in the absence of timely surveillance (Maartje Nielsen
et al., 2012/2015; Lubbe et al., 2009). Biallelic pathogenic variants
in MUTYH have also been described in Lynch and Lynch-like
families in the absence of pathogenic variants in the MMR genes
(Castillejo et al., 2014). Whether monoallelic pathogenic variants
inMUTYH also increase cancer risk is unclear, although there is
some evidence suggesting a slight increase, especially when there
is a family history of colon cancer (Win et al., 2014). The risk for
colorectal cancers for carriers of a pathogenic variant in one of the
MMR genes in addition to a single MUTYH pathogenic variant
was substantially higher than that for carriers of a singleMUTYH
pathogenic variant alone, but not different from that for carriers
of a MMR pathogenic variant alone (Win et al., 2015).
Cases of multiple hereditary cancer syndromes in a family
caused by pathogenic variants in different genes related to two
hereditary cancer syndromes have been previously reported in
the literature (Thiffault et al., 2004; Gong et al., 2012). The
cumulative cancer risks for patients who have both MAP and
Lynch syndrome are not well characterized. There is one previous
report of a patient identified with compound heterozygous
pathogenic variants in MUTYH who also carried a pathogenic
variant in MSH6; this individual exhibited a relatively mild
clinical presentation (van Puijenbroek et al., 2007). To our
knowledge, biallelic MUTYH pathogenic variants in addition to
a pathogenic variant in MSH2, as described in our patient, have
not been previously reported.
DISCUSSION
This case demonstrates several points about genetic testing in
the era of next generation sequencing (NGS) panel testing. First,
had an immunohistochemistry-guided approach to testing been
followed for the proband, the likely pathogenic variant in MSH2
would have been missed. It appears in this case that the proband’s
rectal cancer was a result of the biallelic pathogenic variants in the
MUTYH gene, which would not have resulted in absent MSH2
staining in his tumor. Conversely, his mother’s tumor appears to
be a result of a MMR pathway defect that did result in absent
MSH2/MSH6 staining. A panel was chosen for the proband in
this case due to his diagnosis of colon cancer at a very young age,
the presence of colon polyps, the presence of colorectal cancer
in his father’s family and the possible gynecologic (at the time
unknown) cancer in his mother. There is some recent evidence
that the incidence of pathogenic variants among individuals
diagnosed with colon cancer at a very young age is high, with
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FIGURE 1 | Biallelic MUTYH mutation and likely pathogenic deletion in MSH2. (A) Integrative Genomics Viewer images of next generation sequencing data of
homozygous c.1187G>A (p.Gly396Asp) sequence variant with reference MUTYH nucleotide and amino acid nomenclature indicated. (B) Array CGH image. Red dots
indicate the relevant clinical sample’s log2 ratio confirming duplication of exon 7 in MSH2. Gray dots indicate the log2 ratios for seven other control samples. The
green line indicates the segmentation by the DNA copy R package.
as many as 14–35% of individuals with colon cancer under age
35 found to carry a pathogenic variant in a variety of different
genes (Chubb et al., 2015; Mork et al., 2015). Even considering a
broader age range with diagnoses of colon cancer up to the age
of 50, as many as 15% had an underlying pathogenic variant in a
hereditary cancer gene (Pearlman et al., submitted).
The inheritance patterns for these two genetic conditions are
different. Lynch syndrome is autosomal dominant and MAP is
autosomal recessive. This has significant implications to family
members. Had only the biallelic pathogenic variants in the
MUTYH gene been identified, the proband’s children would have
been falsely reassured that they were just carriers of a single
MUTYH variant. Surveillance recommendations for individuals
who are carriers of a single MUTYH pathogenic variant are
not well defined, but typically would include colonoscopy every
5 years, similar to recommendations for individuals with a
first-degree relative with colorectal cancer (Stoffel et al., 2014;
Provenzale et al., 2015). Surveillance for individuals with a
pathogenic variant in MSH2 is very different, with annual
colonoscopy recommended beginning at age 25 (Provenzale
et al., 2015; Syngal et al., 2015). In addition, surveillance for
other cancers may be considered, such as upper endoscopy, due
to the risks for other cancers associated with Lynch syndrome.
Finally, females are at increased risk for endometrial and
ovarian cancers with Lynch syndrome, so hysterectomy after
childbearing should be considered. As there is variable expression
of MAP and Lynch syndrome in general, the identification of
additional patients with combined diagnoses would be necessary
to makemore definitive conclusions regarding cumulative cancer
risks.
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FIGURE 2 | Family history as reported by proband and his mother.
The proband’s extended family is also impacted by this
complex test result. The determination of the MSH2 duplication
as maternally inherited has implications for maternal family
members, while the cause of the colon cancer in paternal
family members remains unexplained, which may prompt
family members to undergo further analysis. Communication
among family members is very important, especially in cases
where multiple pathogenic variants are identified. There
are at least three affected family members for every person
identified with Lynch syndrome (Hampel et al., 2008). If
this is true when there are multiple pathogenic variants
present, then many more relatives could potentially be
impacted. Sharing of test results among family members
and their doctors is critical to identification of other family
members at risk and recommendations for appropriate
surveillance.
As more genetic testing is completed with NGS panels,
we anticipate a rise in the identification of cases of multiple
pathogenic variants. It is also important for clinicians to be
mindful of the possibility of a second pathogenic variant in a
family where one pathogenic variant has already been described,
particularly in cases where the inheritance patternmay not match
the known pathogenic variant (for example, if the inheritance
appears to be autosomal dominant, but a recessive condition like
MAP is documented), or if the clinical picture doesn’t match the
known pathogenic variant.
CONCLUDING REMARKS
Although the cumulative cancer risk in individuals with a
combined diagnosis of MAP and Lynch syndrome is unknown,
the identification of multiple pathogenic variants does allow
for screening for cancers associated with both genes and has
implications for cancer risk and surveillance recommendations
for family members. In particular, this has significant impact on
those who test negative for a known familial pathogenic variant,
yet could be still be at risk for cancer due to a second pathogenic
variant in a family. More information is needed to understand
the frequency of occurrence of multiple pathogenic variants, as
well as the phenotypic spectrum when more than one syndrome
is present.
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